REM sleep behavior disorder is characterized by the loss of normal muscle atonia during rapid eye movement (REM) sleep, leading patients to physically act out their dreams, often resulting in injury. Historically considered a harbinger of neurodegenerative diseases like Parkinson’s disease and multiple system atrophy, RBD’s association with systemic conditions like IBD has remained elusive until now. This study provides robust epidemiological and clinical evidence supporting a higher prevalence of RBD among individuals suffering from inflammatory bowel disease compared to the general population, suggesting a convergence between chronic immune activation and central nervous system dysfunction.

The researchers conducted a comprehensive cross-sectional analysis involving a large patient cohort diagnosed with various forms of IBD, including Crohn’s disease and ulcerative colitis. Employing validated questionnaires, polysomnography, and detailed clinical assessments, the team meticulously quantified the frequency of RBD symptoms and rigorously controlled for confounding factors such as medication usage, age, and comorbidities. Their findings reveal a statistically significant elevation in the incidence of RBD among IBD patients, indicating that neuroinflammation and gut-brain axis perturbations may play a critical role in the manifestation of sleep disorders.

From a pathophysiological standpoint, this research elucidates potential mechanisms linking intestinal inflammation to disruptions in sleep architecture. Chronic inflammation in IBD induces systemic release of pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which may cross the blood-brain barrier, triggering microglial activation and subsequent neuroinflammation in regions governing sleep regulation, including the pontine tegmentum and the sublaterodorsal nucleus. Such neuroimmune interactions could contribute to the degeneration or functional impairment of inhibitory pathways responsible for muscle atonia during REM sleep.

In addition to inflammatory mediators, gut-derived metabolites and alterations in the enteric nervous system may modulate central nervous system activity. Dysbiosis-driven shifts in microbial populations produce neuroactive compounds such as short-chain fatty acids and tryptophan metabolites that influence neurotransmitter systems regulating sleep and motor control. This study hypothesizes that chronic intestinal dysregulation in IBD creates a milieu conducive to neuronal vulnerability through both direct and indirect mechanisms, heightening susceptibility to RBD.

Importantly, the study also identifies specific risk factors that exacerbate the likelihood of RBD in IBD patients. Disease severity, duration, and extraintestinal manifestations emerged as significant predictors, suggesting that the systemic burden of inflammation potentiates neurological sequelae. Furthermore, the use of certain immunomodulatory therapies appeared to modify RBD risk, underscoring the complex interplay between treatment regimens and neurophysiological outcomes.

The implications of these findings extend beyond mere epidemiological interest. Early identification of RBD in patients with IBD could serve as a crucial biomarker for impending neurodegenerative disease, enabling clinicians to stratify risk and implement preventative strategies. Currently, RBD is viewed as a prodromal marker for synucleinopathies, and its recognition in a population already burdened by chronic immune activation accentuates the necessity for integrated multidisciplinary approaches in patient management.

Moreover, the study calls attention to the gut-brain axis as a fertile ground for translational research. Therapeutic targeting of neuroinflammation, whether through biologics, microbiome modulation, or novel neuroimmune agents, could mitigate the progression of sleep disorders and potentially delay or prevent neurodegeneration in susceptible individuals. The bidirectional communication between the gut and brain, implicated here in sleep pathology, opens new paradigms for understanding how systemic insults manifest as neurological dysfunctions.

The methodological rigor of the study is commendable, incorporating polysomnographic validation of RBD diagnoses to overcome limitations of prior research reliant solely on self-report scales. This objective approach enhances the validity and reproducibility of the results, setting a new standard for future investigations into comorbid sleep disorders in systemic diseases. Additionally, longitudinal follow-up is planned to monitor progression from RBD to overt neurodegenerative syndromes, which will provide critical insights into disease trajectories.

Critically, the research also delves into the neurochemical environment of the brainstem in IBD-induced RBD, using advanced neuroimaging and cerebrospinal fluid analysis to detect markers of synaptic dysfunction and neurodegeneration. Preliminary findings suggest alterations in dopaminergic and cholinergic pathways, consistent with mechanisms implicated in Parkinson’s disease, thereby reinforcing the clinical significance of monitoring sleep disturbances as early neurological indicators.

The authors emphasize the importance of clinician awareness regarding the neurological complications of chronic inflammatory diseases. Gastroenterologists, neurologists, and sleep specialists are encouraged to collaborate closely, ensuring comprehensive screening protocols for RBD symptoms in patients with IBD. Early intervention could dramatically improve patient outcomes, reducing injury risks associated with violent dream enactment and facilitating timely neuroprotective strategies.

In sum, this landmark study not only broadens our understanding of the complex interrelations between chronic intestinal inflammation and central nervous system pathology but also catalyzes a shift toward holistic patient care encompassing neurological and gastrointestinal health. The revelation that RBD prevalence is disproportionately high among IBD sufferers challenges traditional compartmentalization of diseases and highlights the necessity for integrated diagnostic and therapeutic frameworks.

Looking ahead, the research community is poised to explore the molecular underpinnings linking gut inflammation with neurodegenerative processes more deeply. This will involve unraveling the contributions of specific immune pathways, neuronal networks, and microbial factors implicated in sleep disorders, offering tantalizing possibilities for novel interventions. The nexus of sleep medicine, gastroenterology, and neurology revealed by this study represents a cutting-edge frontier in biomedical science.

As we continue to decipher the mysteries of the gut-brain axis, patients with inflammatory bowel disease stand to benefit not only from improved gastrointestinal symptom control but also from advancements in neuroprotective care. This research paves the way for personalized medicine approaches that consider the full spectrum of systemic and neurological health, ultimately enhancing quality of life and long-term prognosis.

The full article by Reddy, V.L., Chen, Z., Dewain, S., et al., titled “Assessing prevalence and risk factors for REM sleep behavior disorder among patients with inflammatory bowel disease,” appears in npj Parkinson’s Disease, volume 11, article 282, 2025. It provides a detailed exploration of the interplay between chronic immune-mediated gastrointestinal disorders and neurodegenerative risk, and its findings are poised to influence clinical practice and research paradigms worldwide.

Subject of Research: Neurodegenerative risk factors associated with REM sleep behavior disorder (RBD) prevalence in patients with inflammatory bowel disease (IBD)

Article Title: Assessing prevalence and risk factors for REM sleep behavior disorder among patients with inflammatory bowel disease

Article References:
Reddy, V.L., Chen, Z., Dewain, S. et al. Assessing prevalence and risk factors for REM sleep behavior disorder among patients with inflammatory bowel disease. npj Parkinsons Dis. 11, 282 (2025). https://doi.org/10.1038/s41531-025-01051-7

Image Credits: AI Generated

In a compelling study published in Cell on September 17, 2025, Stanford researchers have shifted the spotlight to an abnormal type of fat, colloquially termed “creeping fat,” which aggressively envelops the intestines in Crohn’s patients. Unlike benign adiposity, this pathological fat contributes directly to the formation of intestinal fibrosis, a scarring process that stiffens and narrows the bowel in what are known clinically as strictures. This insight reframes creeping fat from a mere symptom of disease to an active player exacerbating the progression of Crohn’s, offering novel molecular targets for intervention that were previously unconsidered.

Crohn’s disease, a perplexing and chronic inflammatory condition of the gastrointestinal tract, generally emerges in adolescence or early adulthood. Patients suffer from a cascade of symptoms—including relentless abdominal pain, diarrhea, malnutrition, and profound fatigue—that deeply impact quality of life. While anti-inflammatory treatments can sometimes achieve remission, a significant subset of patients inevitably progress to develop strictures, a severely fibrotic thickening that impairs intestinal function. Surgical excision remains the primary recourse for strictures; however, this approach is far from ideal, given its invasive nature and the high rate of recurrence.

The challenge in managing strictures lies not only in their physical toll but in their biological complexity. Prior investigations noted the consistent presence of creeping fat adjacent to these scarred intestinal segments, but the mechanistic links remained elusive. This new study, led by pediatric surgeon Jeong Hyun and surgeon-scientist Michael Longaker, probes these mechanisms with unprecedented rigor, combining human tissue analysis and sophisticated animal modeling. Their work reveals that creeping fat houses specialized fibroblasts that are highly responsive to mechanical stress—a factor previously underappreciated in Crohn’s pathogenesis.

Detailed genetic and molecular profiling of fibroblasts within creeping fat tissue discloses a fascinating mechanosensitivity: these cells detect and respond to mechanical strain emanating from the tense, inflamed intestine. This response includes the production of extracellular matrix components, the fundamental constituents of fibrotic scar tissue. Crucially, these activated fibroblasts concentrate at the interface where fat meets intestine, suggesting a localized, dynamic interplay that intensifies tissue stiffening. This insight overturns the conventional mucosa-centric view of Crohn’s, which has historically focused on immune-driven inflammation within the innermost bowel layers.

Equally groundbreaking is the development of an animal model that faithfully recapitulates the human Crohn’s phenotype, including hallmark creeping fat and stricture formation. In this model, mechanical tension of the intestine synergizes with chronic inflammation to activate the fibroblasts in adjacent fat, thereby fueling fibrosis. Such a paradigm foregrounds the role of biomechanical forces alongside immune dysregulation—an integrative perspective that better explains the complex progression of the disease.

The molecular pathways elucidated in this process include the highly conserved YAP/TAZ signaling cascade, known to mediate cellular responses to mechanical stimuli across diverse tissues. Longaker’s laboratory, previously engaged in exploring scar formation in skin, identified that inhibiting YAP/TAZ signaling in fat-resident fibroblasts drastically reduces the fibrotic response in the intestines of diseased mice. This discovery not only implicates a specific, druggable target but also aligns intestinal fibrosis with broader principles of mechanically induced scarring, revealing a potential therapeutic avenue previously untapped in Crohn’s management.

These insights carry profound clinical implications. Current anti-inflammatory regimens address only one facet of Crohn’s pathophysiology—immune activation—while ignoring the potent feedback loop established by creeping fat and mechanosensitive fibrosis. Patients who experience escalating fibrosis despite medication highlight this gap in treatment strategies. The identification of fat-derived fibroblasts as drivers of strictures points toward therapies that could intercept scarring processes before surgery becomes necessary, potentially transforming patient outcomes.

The emotional and physical burden borne by Crohn’s patients is immense. Jeong Hyun, who regularly performs surgeries to excise fibrotic strictures, describes the experience of his patients as one marked by unpredictability and chronic suffering. The inability to control symptom flare-ups or disease progression inflicts a dual hardship—bodily and psychological. This research not only illuminates a path forward scientifically but also holds promise for ameliorating a disease that, until now, offered limited avenues beyond invasive interventions.

Furthermore, the notion of “outside-in” signaling introduced by this study—that inflammation and mechanical forces permeate the full thickness of the bowel wall and the surrounding fat—is a significant conceptual advance. It challenges the prevailing “inside-out” dogma, which confined pathogenetic considerations to layers closest to the intestinal lumen. Recognizing the mesentery and creeping fat as bioactive sites reshapes the therapeutic landscape and necessitates a broader approach to drug development.

This finely detailed exploration also underscores the power of multidisciplinary collaboration. Contributions from institutions beyond Stanford, including Case Western Reserve University and the Icahn School of Medicine at Mt. Sinai, as well as support from a spectrum of funding agencies, illustrate the collective effort required to tackle complex diseases like Crohn’s. Such synergy between surgical insight, molecular biology, and translational research is key to accelerating progress in difficult clinical arenas.

In conclusion, the Stanford-led study reinvents our understanding of fat’s role in Crohn’s disease, transforming creeping fat from a passive marker of disease into a mechanosensitive culprit driving fibrosis. The revelation that biomechanical forces and associated signaling pathways contribute crucially to intestinal scarring underscores the urgency of developing targeted anti-fibrotic therapies. If successful, these could revolutionize care, reducing the need for repeated surgeries and profoundly improving the lives of millions affected by this relentless disease.

Subject of Research: Animals
Article Title: Creeping fat-derived mechanosensitive fibroblasts drive intestinal fibrosis in Crohn’s disease strictures
News Publication Date: 17-Sep-2025
Web References: https://profiles.stanford.edu/jeong-hyun, https://profiles.stanford.edu/michael-longaker, https://profiles.stanford.edu/khristian-bauer-rowe-ramos, https://med.stanford.edu/
References: Study published in Cell, September 17, 2025
Keywords: Crohn disease, inflammatory bowel diseases, intestinal fibrosis, creeping fat, fibroblasts, mechanosensitive signaling, YAP/TAZ pathway, intestinal strictures